Survival in families with hereditary protein C deficiency, 1820 to 1993

OBJECTIVES —To establish the survival of individuals heterozygous for hereditary protein C deficiency, who have an increased risk ofvenous thrombotic events, and to compare it with the survival of the general population. DESIGN —Retrospective study in pedigrees of23 families with hereditary protein...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ 1995-10, Vol.311 (7010), p.910-913
Hauptverfasser: Allaart, C F, Rosendaal, F R, Noteboom, WM P, Vandenbroucke, J P, Briet, E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 913
container_issue 7010
container_start_page 910
container_title BMJ
container_volume 311
creator Allaart, C F
Rosendaal, F R
Noteboom, WM P
Vandenbroucke, J P
Briet, E
description OBJECTIVES —To establish the survival of individuals heterozygous for hereditary protein C deficiency, who have an increased risk ofvenous thrombotic events, and to compare it with the survival of the general population. DESIGN —Retrospective study in pedigrees of23 families with hereditary protein C deficiency for period 1820 and 1993. SETTING —23 completed family trees of 24 probandsfrom various parts of the Netherlands with symptoms of protein C deficiency. SUBJECTS —All 736 members of the 23 families with a50% or 100% probability of being (or having been) heterozygous for the genetic defect on the basis of DNA analysis or their place inthe pedigrees, following mendelian rules. MAIN OUTCOME MEASURES —Observed mortality compared with the mortality of thegeneral Dutch population; the standardised mortality ratio was calculated by dividing the observed mortality by the expected mortality. RESULTS —No excess mortality was found in the 206 proved heterozygous individuals and “obligatory transmitters” (those who havedefinitely passed on the deficiency) (standardised mortality ratio 0.95 (95% confidence interval 0.5 to 1.2)) or in the 530 familymembers with a 50% genetic probability of heterozygosity (1.10 (0.9 to 1.3)). CONCLUSION —Heterozygous individuals withhereditary protein C deficiency type I have normal survival compared with the general population. Prophylactic anticoagulant treatmentmay prevent thrombotic events in heterozygous individuals but may not be expected to improve their survival.
doi_str_mv 10.1136/bmj.311.7010.910
format Article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2550916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>29728993</jstor_id><sourcerecordid>29728993</sourcerecordid><originalsourceid>FETCH-LOGICAL-b515t-b0c355057549ae4211cb5a2e873d3b1a7994ee9a99f5bd9ac3f4a8482da2c8c73</originalsourceid><addsrcrecordid>eNqFkc2L1DAYxoMo67Du3YtQELxox7xJ0yQXQQadVRY9rB_gJaRp6mRsmzFJZ3f_e1NmGD8ungL5PXnyvO-D0GPASwBav2yG7ZICLDnONxLwPbSAqhYlE5TeRwssmSwFUPEQXcS4xRgTyoWs2Rk640xgVvEFWl9PYe_2ui_cWHR6cL2zsbhxaVNsbLCtSzrcFbvgk82CVdHazhlnR3P3ogBBcJF8AVLSR-hBp_toL47nOfr89s2n1WV59XH9bvX6qmwYsFQ22FDGMOOsktpWBMA0TBMrOG1pA5pLWVkrtZQda1qpDe0qLSpBWk2MMJyeo1cH393UDLY1dkxB92oX3JCDKq-d-puMbqO--70i-VsJdTZ4djQI_udkY1KDi8b2vR6tn6LinNG8G5KFT_8Rbv0UxjycAp5VRAKf7fBBZYKPMdjuFAWwmltSuSWVW1JzSyq3lJ88-XOE04NjJ7_5NiYfTphITkTedOblgbuY7O2J6_BD1Zxypj58Wamv364vybp-r2a_5wf9nOS_6X4BajqyQA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777529176</pqid></control><display><type>article</type><title>Survival in families with hereditary protein C deficiency, 1820 to 1993</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Allaart, C F ; Rosendaal, F R ; Noteboom, WM P ; Vandenbroucke, J P ; Briet, E</creator><creatorcontrib>Allaart, C F ; Rosendaal, F R ; Noteboom, WM P ; Vandenbroucke, J P ; Briet, E</creatorcontrib><description>OBJECTIVES —To establish the survival of individuals heterozygous for hereditary protein C deficiency, who have an increased risk ofvenous thrombotic events, and to compare it with the survival of the general population. DESIGN —Retrospective study in pedigrees of23 families with hereditary protein C deficiency for period 1820 and 1993. SETTING —23 completed family trees of 24 probandsfrom various parts of the Netherlands with symptoms of protein C deficiency. SUBJECTS —All 736 members of the 23 families with a50% or 100% probability of being (or having been) heterozygous for the genetic defect on the basis of DNA analysis or their place inthe pedigrees, following mendelian rules. MAIN OUTCOME MEASURES —Observed mortality compared with the mortality of thegeneral Dutch population; the standardised mortality ratio was calculated by dividing the observed mortality by the expected mortality. RESULTS —No excess mortality was found in the 206 proved heterozygous individuals and “obligatory transmitters” (those who havedefinitely passed on the deficiency) (standardised mortality ratio 0.95 (95% confidence interval 0.5 to 1.2)) or in the 530 familymembers with a 50% genetic probability of heterozygosity (1.10 (0.9 to 1.3)). CONCLUSION —Heterozygous individuals withhereditary protein C deficiency type I have normal survival compared with the general population. Prophylactic anticoagulant treatmentmay prevent thrombotic events in heterozygous individuals but may not be expected to improve their survival.</description><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>EISSN: 1756-1833</identifier><identifier>DOI: 10.1136/bmj.311.7010.910</identifier><identifier>PMID: 7580547</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Adolescent ; Adult ; Age Factors ; Age groups ; Aged ; Aged, 80 and over ; Anticoagulants ; Child ; Child, Preschool ; Children ; Death ; DNA ; Family members ; Female ; Heterozygote ; Humans ; Infant ; Male ; Medical genetics ; Middle Aged ; Mortality ; Netherlands ; Pedigree ; Protein C - genetics ; Protein C Deficiency ; Ratios ; Retrospective Studies ; Survival Rate</subject><ispartof>BMJ, 1995-10, Vol.311 (7010), p.910-913</ispartof><rights>1995 BMJ Publishing Group Ltd.</rights><rights>Copyright 1995 British Medical Journal</rights><rights>Copyright: 1995 (c) 1995 BMJ Publishing Group Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b515t-b0c355057549ae4211cb5a2e873d3b1a7994ee9a99f5bd9ac3f4a8482da2c8c73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/29728993$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/29728993$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,799,881,27902,27903,57994,58227</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7580547$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Allaart, C F</creatorcontrib><creatorcontrib>Rosendaal, F R</creatorcontrib><creatorcontrib>Noteboom, WM P</creatorcontrib><creatorcontrib>Vandenbroucke, J P</creatorcontrib><creatorcontrib>Briet, E</creatorcontrib><title>Survival in families with hereditary protein C deficiency, 1820 to 1993</title><title>BMJ</title><addtitle>BMJ</addtitle><description>OBJECTIVES —To establish the survival of individuals heterozygous for hereditary protein C deficiency, who have an increased risk ofvenous thrombotic events, and to compare it with the survival of the general population. DESIGN —Retrospective study in pedigrees of23 families with hereditary protein C deficiency for period 1820 and 1993. SETTING —23 completed family trees of 24 probandsfrom various parts of the Netherlands with symptoms of protein C deficiency. SUBJECTS —All 736 members of the 23 families with a50% or 100% probability of being (or having been) heterozygous for the genetic defect on the basis of DNA analysis or their place inthe pedigrees, following mendelian rules. MAIN OUTCOME MEASURES —Observed mortality compared with the mortality of thegeneral Dutch population; the standardised mortality ratio was calculated by dividing the observed mortality by the expected mortality. RESULTS —No excess mortality was found in the 206 proved heterozygous individuals and “obligatory transmitters” (those who havedefinitely passed on the deficiency) (standardised mortality ratio 0.95 (95% confidence interval 0.5 to 1.2)) or in the 530 familymembers with a 50% genetic probability of heterozygosity (1.10 (0.9 to 1.3)). CONCLUSION —Heterozygous individuals withhereditary protein C deficiency type I have normal survival compared with the general population. Prophylactic anticoagulant treatmentmay prevent thrombotic events in heterozygous individuals but may not be expected to improve their survival.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Age groups</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Death</subject><subject>DNA</subject><subject>Family members</subject><subject>Female</subject><subject>Heterozygote</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Medical genetics</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Netherlands</subject><subject>Pedigree</subject><subject>Protein C - genetics</subject><subject>Protein C Deficiency</subject><subject>Ratios</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><issn>0959-8138</issn><issn>1468-5833</issn><issn>1756-1833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc2L1DAYxoMo67Du3YtQELxox7xJ0yQXQQadVRY9rB_gJaRp6mRsmzFJZ3f_e1NmGD8ungL5PXnyvO-D0GPASwBav2yG7ZICLDnONxLwPbSAqhYlE5TeRwssmSwFUPEQXcS4xRgTyoWs2Rk640xgVvEFWl9PYe_2ui_cWHR6cL2zsbhxaVNsbLCtSzrcFbvgk82CVdHazhlnR3P3ogBBcJF8AVLSR-hBp_toL47nOfr89s2n1WV59XH9bvX6qmwYsFQ22FDGMOOsktpWBMA0TBMrOG1pA5pLWVkrtZQda1qpDe0qLSpBWk2MMJyeo1cH393UDLY1dkxB92oX3JCDKq-d-puMbqO--70i-VsJdTZ4djQI_udkY1KDi8b2vR6tn6LinNG8G5KFT_8Rbv0UxjycAp5VRAKf7fBBZYKPMdjuFAWwmltSuSWVW1JzSyq3lJ88-XOE04NjJ7_5NiYfTphITkTedOblgbuY7O2J6_BD1Zxypj58Wamv364vybp-r2a_5wf9nOS_6X4BajqyQA</recordid><startdate>19951007</startdate><enddate>19951007</enddate><creator>Allaart, C F</creator><creator>Rosendaal, F R</creator><creator>Noteboom, WM P</creator><creator>Vandenbroucke, J P</creator><creator>Briet, E</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><general>BMJ Group</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>LK8</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19951007</creationdate><title>Survival in families with hereditary protein C deficiency, 1820 to 1993</title><author>Allaart, C F ; Rosendaal, F R ; Noteboom, WM P ; Vandenbroucke, J P ; Briet, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b515t-b0c355057549ae4211cb5a2e873d3b1a7994ee9a99f5bd9ac3f4a8482da2c8c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Age groups</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Death</topic><topic>DNA</topic><topic>Family members</topic><topic>Female</topic><topic>Heterozygote</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Medical genetics</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Netherlands</topic><topic>Pedigree</topic><topic>Protein C - genetics</topic><topic>Protein C Deficiency</topic><topic>Ratios</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Allaart, C F</creatorcontrib><creatorcontrib>Rosendaal, F R</creatorcontrib><creatorcontrib>Noteboom, WM P</creatorcontrib><creatorcontrib>Vandenbroucke, J P</creatorcontrib><creatorcontrib>Briet, E</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Allaart, C F</au><au>Rosendaal, F R</au><au>Noteboom, WM P</au><au>Vandenbroucke, J P</au><au>Briet, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival in families with hereditary protein C deficiency, 1820 to 1993</atitle><jtitle>BMJ</jtitle><addtitle>BMJ</addtitle><date>1995-10-07</date><risdate>1995</risdate><volume>311</volume><issue>7010</issue><spage>910</spage><epage>913</epage><pages>910-913</pages><issn>0959-8138</issn><eissn>1468-5833</eissn><eissn>1756-1833</eissn><abstract>OBJECTIVES —To establish the survival of individuals heterozygous for hereditary protein C deficiency, who have an increased risk ofvenous thrombotic events, and to compare it with the survival of the general population. DESIGN —Retrospective study in pedigrees of23 families with hereditary protein C deficiency for period 1820 and 1993. SETTING —23 completed family trees of 24 probandsfrom various parts of the Netherlands with symptoms of protein C deficiency. SUBJECTS —All 736 members of the 23 families with a50% or 100% probability of being (or having been) heterozygous for the genetic defect on the basis of DNA analysis or their place inthe pedigrees, following mendelian rules. MAIN OUTCOME MEASURES —Observed mortality compared with the mortality of thegeneral Dutch population; the standardised mortality ratio was calculated by dividing the observed mortality by the expected mortality. RESULTS —No excess mortality was found in the 206 proved heterozygous individuals and “obligatory transmitters” (those who havedefinitely passed on the deficiency) (standardised mortality ratio 0.95 (95% confidence interval 0.5 to 1.2)) or in the 530 familymembers with a 50% genetic probability of heterozygosity (1.10 (0.9 to 1.3)). CONCLUSION —Heterozygous individuals withhereditary protein C deficiency type I have normal survival compared with the general population. Prophylactic anticoagulant treatmentmay prevent thrombotic events in heterozygous individuals but may not be expected to improve their survival.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>7580547</pmid><doi>10.1136/bmj.311.7010.910</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0959-8138
ispartof BMJ, 1995-10, Vol.311 (7010), p.910-913
issn 0959-8138
1468-5833
1756-1833
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2550916
source Jstor Complete Legacy; MEDLINE; Alma/SFX Local Collection
subjects Adolescent
Adult
Age Factors
Age groups
Aged
Aged, 80 and over
Anticoagulants
Child
Child, Preschool
Children
Death
DNA
Family members
Female
Heterozygote
Humans
Infant
Male
Medical genetics
Middle Aged
Mortality
Netherlands
Pedigree
Protein C - genetics
Protein C Deficiency
Ratios
Retrospective Studies
Survival Rate
title Survival in families with hereditary protein C deficiency, 1820 to 1993
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T08%3A45%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20in%20families%20with%20hereditary%20protein%20C%20deficiency,%201820%20to%201993&rft.jtitle=BMJ&rft.au=Allaart,%20C%20F&rft.date=1995-10-07&rft.volume=311&rft.issue=7010&rft.spage=910&rft.epage=913&rft.pages=910-913&rft.issn=0959-8138&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.311.7010.910&rft_dat=%3Cjstor_pubme%3E29728993%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777529176&rft_id=info:pmid/7580547&rft_jstor_id=29728993&rfr_iscdi=true